Pfizer Eyes First-To-Market Opportunity In Alopecia
Inflammation and Immunology Chief Scientific Officer Michael Vincent talked to Scrip about the first positive Phase II data testing a JAK inhibitor for hair loss caused by alopecia areata, next steps for development and the broader I&I portfolio.
You may also be interested in...
Concert believes its deuterated form of ruxolitinib has a better overall profile in alopecia areata than Pfizer’s JAK3 inhibitor. The company is planning to meet with the FDA to plan a Phase III program early in 2020.
Albert Bourla will face opportunities and potential pitfalls.
The company's first set of Phase II data for its oral, selective TYK2 inhibitor in psoriasis showed a consistent dose response as well as safety that could rival the related JAK inhibitor class. BMS-986165 already is in Phase III for psoriasis; it's in Phase II for lupus and Crohn's disease.